{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:41:43Z","timestamp":1777480903109,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T00:00:00Z","timestamp":1640736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T00:00:00Z","timestamp":1640736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite improvements in the treatment of myocardial infarction (MI), risk-associated management disparities may exist. We investigated this issue including temporal trends in a large MI cohort (n\u2009=\u2009179,291) registered 2005\u20132017 in SWEDEHEART. Multivariable models were used to study the associations between risk categories according to the GRACE 2.0 score and coronary procedures (timely reperfusion, invasive assessment\u2009\u2264\u20093\u00a0days, in-hospital coronary revascularization), pharmacological treatments (P2Y12-blockers, betablockers, renin\u2013angiotensin\u2013aldosterone-system [RAAS]-inhibitors, statins), structured follow-up and secondary prevention (smoking cessation, physical exercise training). High-risk patients (n\u2009=\u200976,295 [42.6%]) experienced less frequent medical interventions compared to low\/intermediate-risk patients apart from betablocker treatment. Overall, intervention rates increased over time with more pronounced increases seen in high-risk patients compared to lower-risk patients for in-hospital coronary revascularization (+\u200923.6% vs.\u2009+\u200912.5% in patients\u2009&lt;\u200980\u00a0years) and medication with P2Y12-blockers (+\u200922.2% vs.\u2009+\u20097.8%). However, less pronounced temporal increases were noted in high-risk patients for medication with RAAS-blockers (+\u20098.5% vs.\u2009+\u200913.0%) and structured follow-up (+\u200931.6% vs.\u2009+\u200936.3%); <jats:italic>p<\/jats:italic><jats:sub>interaction<\/jats:sub>\u2009&lt;\u20090.001 for all. In conclusion, management\u00a0of high-risk patients with MI is improving. However, the lower rates of follow-up and of RAAS-inhibitor\u00a0prescription are a concern. Our data emphasize the need of continuous quality improvement initiatives.<\/jats:p>","DOI":"10.1038\/s41598-021-03742-6","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T11:03:21Z","timestamp":1640775801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Risk-associated management disparities in acute myocardial infarction"],"prefix":"10.1038","volume":"11","author":[{"given":"Kai M.","family":"Eggers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Jernberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Lindahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,29]]},"reference":[{"key":"3742_CR1","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.jacc.2011.06.050","volume":"58","author":"AA Motivala","year":"2011","unstructured":"Motivala, A. A. et al. Changes in myocardial infarction guideline adherence as a function of patient risk: An end to paradoxical care?. J. Am. Coll. Cardiol. 58, 1760\u20131765 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3742_CR2","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1093\/eurheartj\/ehx515","volume":"38","author":"K Szummer","year":"2017","unstructured":"Szummer, K. et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: Experiences from the SWEDEHEART registry 1995\u20132014. Eur. Heart J. 38, 3056\u20133065 (2017).","journal-title":"Eur. Heart J."},{"key":"3742_CR3","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1093\/eurheartj\/ehy554","volume":"39","author":"K Szummer","year":"2018","unstructured":"Szummer, K. et al. Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: Experiences from SWEDEHEART registry 1995 to 2014. Eur. Heart J. 39, 3766\u20133776 (2018).","journal-title":"Eur. Heart J."},{"key":"3742_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ijcard.2018.08.015","volume":"272","author":"A Saar","year":"2018","unstructured":"Saar, A. et al. The risk-treatment paradox in non-ST-elevation myocardial infarction patients according to their estimated GRACE risk. Int. J. Cardiol. 272, 26\u201332 (2018).","journal-title":"Int. J. Cardiol."},{"key":"3742_CR5","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1093\/eurheartj\/ehy517","volume":"39","author":"M Hall","year":"2018","unstructured":"Hall, M. et al. Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. Eur. Heart J. 39, 3798\u20133806 (2018).","journal-title":"Eur. Heart J."},{"key":"3742_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijcard.2017.11.018","volume":"255","author":"FP Schmidt","year":"2018","unstructured":"Schmidt, F. P. et al. Invasive treatment of NSTEMI patients in German chest pain units\u2014Evidence for a treatment paradox. Int. J. Cardiol. 255, 15\u201319 (2018).","journal-title":"Int. J. Cardiol."},{"key":"3742_CR7","doi-asserted-by":"publisher","first-page":"e004425","DOI":"10.1136\/bmjopen-2013-004425","volume":"4","author":"KA Fox","year":"2014","unstructured":"Fox, K. A. et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open 4, e004425 (2014).","journal-title":"BMJ Open"},{"key":"3742_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet, J. P. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 42, 1289\u20131367 (2021).","journal-title":"Eur. Heart J."},{"key":"3742_CR9","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","volume":"72","author":"K Thygesen","year":"2018","unstructured":"Thygesen, K. et al. Fourth universal definition of myocardial infarction (2018). J. Am. Coll. Cardiol. 72, 2231\u20132264 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3742_CR10","unstructured":"SWEDEHEART. Kvalitetsindex 2017. https:\/\/www.ucr.uu.se\/swedeheart\/dokument-sh\/kvalitetsindex\/kvalitetsindex-2017 (2017)."},{"key":"3742_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/archinternmed.2007.78","volume":"168","author":"CH Lee","year":"2008","unstructured":"Lee, C. H. et al. Use of cardiac catheterization for non-ST-segment elevation acute coronary syndromes according to initial risk: Reasons why physicians choose not to refer their patients. Arch. Intern. Med. 168, 291\u2013296 (2008).","journal-title":"Arch. Intern. Med."},{"key":"3742_CR12","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1016\/j.jacc.2010.03.007","volume":"55","author":"KA Fox","year":"2010","unstructured":"Fox, K. A. et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J. Am. Coll. Cardiol. 55, 2435\u20132445 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3742_CR13","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam, E. A. et al. 2014 AHA\/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 64, e139\u2013e228 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3742_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/eurheartj\/ehaa927","volume":"42","author":"TA Kite","year":"2021","unstructured":"Kite, T. A. & Gershlick, A. H. High-risk NSTE-ACS: High time for robust data. Eur. Heart J. 42, 352 (2021).","journal-title":"Eur. Heart J."},{"key":"3742_CR15","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","volume":"97","author":"ACE Inhibitor Myocardial Infarction Collaborative Group","year":"1998","unstructured":"ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systemic overview of individual data from 100,000 patients in randomized trials. Circulation 97, 2202\u20132212 (1998).","journal-title":"Circulation"},{"key":"3742_CR16","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1161\/CIRCULATIONAHA.107.182616","volume":"115","author":"KP Alexander","year":"2007","unstructured":"Alexander, K. P. et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: A scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: In collaboration with the Society of Geriatric Cardiology. Circulation 115, 2570\u20132589 (2007).","journal-title":"Circulation"},{"key":"3742_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2015.10.044","volume":"67","author":"L Anderson","year":"2016","unstructured":"Anderson, L. et al. Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. J. Am. Coll. Cardiol. 67, 1\u201312 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3742_CR18","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1136\/hrt.2010.198804","volume":"96","author":"T Jernberg","year":"2010","unstructured":"Jernberg, T. et al. The Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart 96, 1617\u20131621 (2010).","journal-title":"Heart"},{"key":"3742_CR19","unstructured":"SWEDEHEART. Infarktdefinition 140515_KE (2). https:\/\/www.ucr.uu.se\/swedeheart\/dokument-rikshia\/ovriga-dokument-rikshia (2014)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03742-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03742-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03742-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T18:37:59Z","timestamp":1670092679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03742-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,29]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3742"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03742-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,29]]},"assertion":[{"value":"5 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.E. reports personal fees from Roche Diagnostics outside this study. T.J. reports institutional grants from Novartis and reimbursement from Astra-Zeneca, Bayer and Sanofi for lecturing and consulting outside this study. B.L. had no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24488"}}